Brief: Alligator And Orion Develop Option Under 2021 Collaboration And License Agreement
April 26 (Reuters) - Alligator Bioscience ATORX.ST :
* ALLIGATOR BIOSCIENCE AND ORION CORPORATION ANNOUNCE
EXERCISE OF
DEVELOPMENT OPTION UNDER 2021 IMMUNO-ONCOLOGY RESEARCH
COLLABORATION AND LICENSE AGREEMENT
* ALLIGATOR BIOSCIENCE AB - EXERCISE OF THIS DEVELOPMENT
OPTION
TRIGGERS AN UNDISCLOSED MILESTONE PAYMENT TO ALLIGATOR
Source text for Eikon: ID:nMFN8MFN2D
Further company coverage: ATORX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Alligator Bioscience AB
See all newsBrief: Alligator Bioscience Q1 Net Loss SEK 1.4 Million
Sweden's Alligator Bioscience posts Q1 net profit, narrows operating loss
Brief: Alligator Bioscience Q1 EBIT SEK -17.8 Million
Brief: Alligator Bioscience Signs LoI With Unicancer For Phase 3 Mitazalimab Development
Brief: Exercise Of Warrants Brings Alligator Bioscience Net Proceeds Of SEK 12 Mln